Can You Take Wegovy If You Have Gallstones?

You've been told you have gallstones. Now your GP has mentioned Wegovy might help with your weight.

That's a situation our prescribers hear about regularly. Gallstones are common in people with obesity, so the two conditions often turn up together. The difficulty is that semaglutide (the medicine in Wegovy) is associated with gallbladder side effects, and the same is true of GLP-1 medicines as a class. Faster weight loss from any cause can shift the cholesterol balance in bile, which in turn can encourage stones to form or existing ones to move. The Wegovy SmPC, published on the Electronic Medicines Compendium, lists gallstones, gallbladder inflammation and bile duct stones among the recognised adverse effects of semaglutide.

That doesn't mean the medicine is off the table if you have gallstones. It means the conversation matters. A prescriber reviewing your case will want to know whether your gallstones are currently asymptomatic, whether you've had episodes of biliary colic, whether your gallbladder is still intact, and whether you're already under a specialist. Someone with a long-standing, incidental finding of small silent stones is a different clinical picture from someone who had an acute cholecystitis three months ago. The page covering the relationship between Wegovy and gallstones goes into more depth on how prescribers weigh this.

Worth knowing, too: semaglutide isn't the only GLP-1 medicine with this consideration. If you're wondering whether the same applies to can you take semaglutide if you have gallstones in a broader sense, the answer is yes, it applies across preparations of the drug, and our dedicated page on Wegovy and gall stones covers what that means in practice for people already living with the condition.

What the clinical evidence actually shows about gallbladder risk

The STEP clinical trials, which tested semaglutide 2.4mg against placebo in adults with obesity, did find higher rates of gallbladder-related events in the semaglutide group than in the placebo group. Most of these events were cholelithiasis (new gallstone formation) rather than acute emergencies, and they occurred more often in the earlier months of treatment when weight loss is fastest. This pattern fits with what we know about rapid weight loss from any source: the liver releases more cholesterol into bile during periods of active fat loss, which can supersaturate bile and favour stone formation.

The NHS's patient guidance on semaglutide lists gallbladder problems among the side effects to be aware of, and flags abdominal pain as something to take seriously. That context matters if you already have stones: the threshold for seeking medical attention should be lower, and any new or worsening upper right abdominal pain (particularly after eating fatty food) deserves prompt assessment rather than waiting to see if it settles.

Gallbladder side effects were generally uncommon in absolute terms in the trials, but for someone with pre-existing gallstone disease the relative risk picture shifts. Your prescriber will consider whether the benefit of treatment (substantial weight reduction and its associated health gains) outweighs that added risk for your specific situation. That's not a calculation anyone can make from a website; it needs a clinical review of your full history.

Symptoms to take seriously if you start Wegovy with a gallbladder history

If a prescriber decides treatment is appropriate for you, knowing which symptoms need urgent attention is important. Gallbladder pain typically presents as pain in the upper right abdomen or between the shoulder blades, often coming on after a meal and lasting from a few minutes to several hours. Fever alongside that pain can indicate gallbladder inflammation rather than simple colic, and that's a same-day call to your GP or, if severe, a 999 situation.

Jaundice (yellowing of the skin or whites of the eyes) alongside abdominal pain may suggest a stone has moved into the bile duct, which needs urgent medical review. Our prescribers include this kind of monitoring conversation as part of aftercare; if you have questions between orders, the support team can direct you to the right clinical channel. Separately, the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is there for reporting any suspected side effect during treatment, it's genuinely useful for building the safety picture on medicines like Wegovy that are still under additional MHRA monitoring.

It's also worth understanding that GLP-1 medicines slow gastric emptying, which changes gallbladder contraction patterns. Some people with an existing gallbladder condition find their symptoms shift during treatment. Keeping a brief note of any new abdominal symptoms in the first weeks is a practical habit, one that makes the conversation with your prescriber at your next review much more useful. You can read more about how Wegovy interacts with other digestive conditions on the page covering Wegovy and GORD, which runs through similar considerations around the gut.

How a prescriber makes the decision, and what to bring to that conversation

If you're exploring treatment options and want to understand whether Wegovy could be right for you despite a gallbladder history, the most useful thing you can do before any consultation is gather the specifics: when gallstones were diagnosed, how they were found (often incidentally on a scan for something else), whether you've had any related symptoms or hospital admissions, and whether you still have your gallbladder. If you've had a cholecystectomy, the risk profile changes significantly, the gallbladder is no longer there to become inflamed, though bile duct considerations remain, and our guide on how to mix a semaglutide cartridge is worth reading ahead of starting treatment so you're confident with the preparation process from day one.

A prescriber at a service like ours can consider all of this alongside your BMI, any weight-related conditions, and your overall health picture. Wegovy is licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure or type 2 diabetes, lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But licensing is the starting point, not the whole answer; individual suitability is what matters. You can explore the broader picture of how semaglutide is used on the semaglutide overview page, or look at the Wegovy treatment page for the full context on this medicine specifically.

Wegovy is also available through the NHS via specialist weight management services under NICE guidance, but waiting lists are often long, and private treatment through a regulated pharmacy is the alternative for people who either don't meet NHS criteria or simply can't wait. If you'd like to understand your treatment options and discuss your gallbladder history with a clinician, the free consultation is the right place to start.